LOXL2 and Interstitial cardiac fibrosis: The efficacy of anti-LOXL2 antibody and genetic LOXL2 disruption in relieving cardiac interstitial fibrosis and diastolic abnormalities is particularly salient, given the lack of direct therapy against cardiac fibrosis, and the increasing emphasis on diastolic dysfunction as an integral part of the heart failure syndrome.